Open AccessImmunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
Author(s) -
Tian-Tian Xuan,
Guangyi Li,
Si-bo Meng,
Zhan-Mei Wang,
Linli Qu
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i23.8284
Subject(s) - medicine , pembrolizumab , bevacizumab , immunotherapy , chemotherapy , mesothelioma , oncology , pleural disease , respiratory disease , cancer , pathology , lung
Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies.